Fodisis Adverse Reactions

Fluconazole is generally well tolerated.
The most common adverse reactions associated with Fluconazole are: Nervous system disorders: Headache.
Gastrointestinal disorders: Abdominal pain, diarrhea, flatulence, nausea.
Hepatobiliary disorders: Hepatic toxicity including rare cases of fatalities, elevated alkaline phosphatase, elevated bilirubin, elevated SGOT, elevated SGPT.
Skin and subcutaneous tissue disorders: Rash.
In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal, and hematological function test results and hepatic abnormalities (see Precautions) have been observed during treatment with Fluconazole and comparative agents, but the clinical significance and relationship to treatment is uncertain.
Psychiatric disorders (uncommon): Insomnia, somnolence.
Ear and labyrinth disorders (uncommon): Vertigo.
Musculoskeletal, connective tissue and bone disorders (uncommon): Myalgia.
General disorders and administration site conditions (uncommon): Fatigue, malaise, asthenia, fever.
Skin and subcutaneous tissue disorders (uncommon): Increased sweating, drug eruption, acute generalized exanthematous-pustulosis (rare).
Hepatobiliary disorders (rare): Hepatocellular damage.
In addition, the following adverse effects have occurred during post-marketing: Blood and lymphatic system disorders: Leukopenia including neutropenia and agranulocytosis, thrombocytopenia.
Immune system disorders: Anaphylaxis (including angioedema, face edema pruritus, urticaria).
Metabolism and nutrition disorders: Hypercholesterolemia, hypertriglyceridemia, hypokalemia.
Nervous system disorders: Dizziness, seizures, paresthesia, taste perversion, tremor.
Cardiac disorders: QT prolongation, torsades de pointes (see Precautions).
Gastrointestinal disorders: Dyspepsia, vomiting, dry mouth.
Hepatobiliary disorders: Hepatic failure, hepatitis, hepatocellular necrosis, jaundice.
Skin and subcutaneous tissue disorders: Alopecia, exfoliate skin disorders including Stevens-Johnson syndrome and toxic epidermal necrolysis.